Diakonos Research

Diakonos Research is a clinical-stage immuno-oncology company based in Houston, Texas, focused on developing personalized dendritic cell vaccines for difficult-to-treat cancers. The company's proprietary Double Loading technology mimics a natural viral infection to activate a robust, patient-specific T-cell response against tumors. Its lead candidate, DOC1021, is currently in Phase 1/2 clinical trials for the treatment of glioblastoma multiforme (GBM), where it has demonstrated significant improvements in median overall survival. Beyond GBM, Diakonos is expanding its pipeline to include treatments for pancreatic cancer and angiosarcoma. By leveraging the body's innate immune signaling without the need for genetic modification, the company aims to provide highly targeted therapies with a superior safety profile compared to traditional treatments.